PRKCE and metabolic dysfunction-associated steatotic liver disease: These findings offer further evidence for the role of plasma membrane sn-1,2-DAG -induced PKCε activation in causing hepatic insulin resistance and support the potential utility of CRMP and other liver-targeted mitochondrial protonophores for the treatment of NAFLD associated with reduced MTTP activity.